AUTHORS
Kari Brown, MD, MS, John O. Mascarenhas, MD2, John Crispino, PhD3, Ronald Hoffman, MD4, Gillian Sanchez5, Heidi Kosiorek, MS6, Amylou C Dueck, PhD7, Anthony Michael Hunter, MD8
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
7 Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
8 Emory Winship Cancer Institute, Atlanta, Georgia, United States
ABSTRACT
Background & Significance
Myelofibrosis (MF) is a BCR::ABL-negative myeloproliferative neoplasm (MPN) characterized by clonal proliferation of abnormal hematopoietic stem cells and progressive bone marrow fibrosis leading to debilitating constitutional symptoms, splenomegaly and progressive cytopenias, with risk of leukemic transformation and median overall survival of 5-7 years. The advent of JAK inhibitors, which target constitutively active JAK/STAT signaling, has led to considerable improvements in symptom and spleen burden. Yet, nearly all patients will eventually discontinue therapy because of resistance, intolerance or suboptimal response, with limited subsequent treatment options, particularly in patients ineligible for potentially curative hematopoietic stem cell transplantation. There is an urgent need for novel therapies targeting relevant alternative pathways of MF pathogenesis such as the pathophysiologic hallmark of megakaryocyte proliferation and atypia. Revumenib is a small-molecule inhibitor of the menin-KMT2A interaction, a critical epigenetic regulator of oncogene expression currently used in relapsed/refractory NPM1 and KMT2Ar-AML. Recent promising pre-clinical data from the Crispino laboratory have demonstrated the ability of revumenib to inhibit formation of MPN megakaryocyte progenitors in vitro, and improve bone marrow fibrosis and inflammation in MPN mouse models.(Wen et al., 2026)
Study Design & Methods
This is an open-label phase Ib/II multi-center investigator-initiated clinical trial that will be conducted within the MPN-Research Consortium. The trial will evaluate the safety and efficacy of revumenib in two separate sequentially enrolled cohorts of patients with MF.
Cohort 1 (revumenib monotherapy) will enroll participants who have discontinued at least one prior JAK inhibitor due to lack of response, loss of response, or intolerance, and require therapeutic intervention to address signs of active disease including splenomegaly (spleen > 450 cm3 or palpable ≥5 cm below the left costal margin), symptom burden (total symptom score > 10 measured by MF-SAF v4.0), or transfusion-dependent anemia. This phase of the study will follow a 3+3 dose-escalation design with primary endpoint to establish safety and tolerability assessed as the occurrence of dose limiting toxicities (DLTs) during the first 2 cycles of therapy. Between 6 and 12 participants will be enrolled to establish the maximum tolerated dose (MTD); the target will be 270mg twice daily (160mg twice daily in participants receiving strong CYP3A4 inhibitors), based on established data in AML.
Following confirmation of the safety and MTD of revumenib in Cohort 1, enrollment will proceed to Cohort 2 (revumenib combination therapy). Cohort 2 will enroll MF participants receiving a stable dose of JAK inhibitor (ruxolitinib, fedratinib, or momelotinib) for at least 12 weeks and who continue to have evidence of active disease as described previously. Participants will be treated with revumenib at the MTD established in Cohort 1, and will continue the prior stable dose of JAK inhibitor. Participants will be treated for a total of 6 cycles (24 weeks) of therapy, with efficacy assessments at 12 and 24 weeks to include volumetric spleen analysis by MRI/CT, assessment of symptom burden by MF-SAF, anemia response based on peripheral blood analysis and bone marrow biopsy (at C7D1 only). The Cohort 2 primary endpoint will be overall response rate (ORR), defined as complete response, partial response, or clinical improvement by revised IWG-MRT and ELN criteria after 6 cycles (C7D1). Up to 20 patients will be enrolled, using the Bayesian optimal phase II (BOP2) design with interim stopping boundary for efficacy. If 1 or fewer responses (measured as ORR) occur in the first 10 participants, the study will be halted. Sequential boundaries will be used to monitor toxicity (measured as DLTs attributable to the study treatment) across all cycles in Cohort 2.
Secondary endpoints in both cohorts will include adverse events using CTCAE v6.0 and progression free survival (PFS). This study will also explore correlative endpoints to assess changes in gene expression of key menin transcriptional targets, inflammatory cytokines, circulating CD34+ cells, JAK2/MPL/CALR variant allele frequency and bone marrow histopathologic features. This trial is registered on clinicaltrials.gov (NCT07734077) and is expected to begin accrual in 2026.
DISCLOSURES
Kari Brown, MD, MS: No relevant conflicts of interest to declare.